Nobel laureate heads up NCI

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 19 No 6
Volume 19
Issue 6

Harold E. Varmus, MD, has been nominated by President Barack Obama to serve as the director of the NCI.

Harold E. Varmus, MD, has been nominated by President Barack Obama to serve as the director of the NCI. Dr. Varmus most recently served as president and CEO of Memorial Sloan-Kettering Cancer Center in New York. Dr. Varmus, J. Michael Bishop, MD, and colleagues won the 1989 Nobel Prize for Physiology or Medicine when they demonstrated the cellular origins of the oncogene of a chicken retrovirus. This led to the isolation of cellular genes that control growth and development and are frequently mutated in human cancer. The NCI directorship will be Dr. Varmus' second go-round heading up a federal institution: He served as director of the NIH from 1993 to 1999.

Articles in this issue
Nobel laureate heads up NCI
Cleveland Clinic nets federal funds for research facility revamp
Diabetes drug acts as chemopreventive in smokers
FTC extends deadline for Red Flags Rule on patient privacy
From the ONI archives: Ofatumumab turns in encouraging results in pretreated CLL
Studies strengthen connection between mammographic breast density and a woman’s risk of breast cancer
Excess weight, smoking may influence risk of disease relapse after prostate cancer treatment
Breakthrough cancer-related pain: The truth hurts
African-American genetic mutations pose Rx challenge
African-American genetic mutations pose Rx challenge
Personalized medicine advances in non-small–cell lung cancer treatment
PET unable to reliably identify post-Rx colon mets
Medicare study questions use of high-tech cancer imaging
Who's News

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.